Analyzing HUTCHMED (NASDAQ:HCM) & Autolus Therapeutics (NASDAQ:AUTL)

HUTCHMED (NASDAQ:HCM) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for HUTCHMED and Autolus Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1	3	1	1	2.33
Autolus Therapeutics	2	0	5	0	2.43

HUTCHMED currently has a consensus price target of $16.88, suggesting a potential upside of 20.71%. Autolus Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 490.28%. Given Autolus Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than HUTCHMED.

Profitability

This table compares HUTCHMED and Autolus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Autolus Therapeutics	-439.69%	-63.76%	-30.88%

Insider and Institutional Ownership

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares HUTCHMED and Autolus Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51 million	4.45	$456.91 million	N/A	N/A
Autolus Therapeutics	$51.13 million	7.50	-$220.66 million	($0.83)	-1.73

HUTCHMED has higher revenue and earnings than Autolus Therapeutics.

Risk & Volatility

HUTCHMED has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.

Summary

Autolus Therapeutics beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.